

Impulse Dynamics' Optimizer Receives nod of CFDA

19 December 2017 | News

The CFDA approves Impulse Dynamics' Optimizer System for treatment of chronic heart failure



Dr. Simos Kedikoglou, CEO of Impulse Dynamics announced about the approval of Impulse Dynamics' Optimizer system by China Food and Drug Administration (CFDA).

This optimizer system is used for the treatment of chronic heart failure.

The implantable Optimizer device delivers non-excitatory Cardiac Contractility Modulation signals to the heart muscle, and initiates multiple biochemical and neurohormonal changes to the myocardium.

As a result, the contractility of the myocardium increases with no concomitant increase in oxygen consumption, enabling the heart to operate more efficiently.

The Optimizer® has been successfully implanted in over 3,500 patients worldwide to date, and Cardiac Contractility Modulation technology is approved for sale in Europe, Australia, Brazil, India, New Zealand and Hong Kong.

The device is also referenced in the 2016 European Heart Failure Association guidelines as a potential treatment for heart failure patients.

Impulse Dynamics is progressively working in China and making the Optimizer and Cardiac Contractility Modulation available to Chinese heart failure patients.

Eventually The Company is planning to start commercial sales of this device in China.